Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis

Cancer Biology and Therapy

Volumn 9, Issue 12, 2010, Pages 967-974

  Yang, Jun ^a   Chen, Shuqin ^b   Huang, Xuan ^b   Han, Jiande ^b   Wang, Qingsong ^a   Shi, Dingbo ^a   Cheng, Rui ^a   Gao, Guoquan ^a   Yang, Xia ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiogenesis; Cervical cancer; HIF 1 ; PEDF; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; PIGMENT EPITHELIUM DERIVED FACTOR; RECOMBINANT PIGMENT EPITHELIUM DERIVED FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; ENDOTHELIUM CELL; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL HYPOXIA; DOWN-REGULATION; ENDOTHELIAL CELLS; EYE PROTEINS; FEMALE; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; RECOMBINANT PROTEINS; SERPINS; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77954396771     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.12.11635     Document Type: Article

References (35)

1. World Health Organization. Comprehensive cervical cancer control: A guide to essential practice. Geneva: WHO 2006.
2. Fujimoto J. Novel strategy of anti-angiogenic therapy for uterine cervical carcinomas. Anticancer Res 2009; 29:2665-9.
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29:15-8.
4. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653-60.
5. Ozalp S, Yalcin OT, Oner U, Tanir HM, Acikalin M, Sarac I. Microvessel density as a prognostic factor in preinvasive and invasive cervical lesions. Eur J Gynaecol Oncol 2003; 24:425-8. (Pubitemid 37236572)
6. No JH, Jo H, Kim SH, Park IA, Kang D, Han SS, et al. Expression of vascular endothelial growth factor and hypoxia inducible factor-1alpha in cervical neoplasia. Ann N Y Acad Sci 2009; 1171:105-10.
7. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999; 285:245-8.
8. Filleur S, Nelius T, de Riese W, Kennedy RC. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem 2009; 106:769-75.
9. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, et al. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002; 8:349-57.
10. Ho TC, Chen SL, Yang YC, Liao CL, Cheng HC, Tsao YP. PEDF induces p53-mediated apoptosis through PPARgamma signaling in human umbilical vein endothelial cells. Cardiovasc Res 2007; 76:213-23.
11. Ho TC, Chen SL, Yang YC, Lo TH, Hsieh JW, Cheng HC, et al. Cytosolic phospholipase A2-{alpha} is an early apoptotic activator in PEDF-induced endothelial cell apoptosis. Am J Physiol Cell Physiol 2009; 296:273-84.
12. Garcia M, Fernandez-Garcia NI, Rivas V, Carretero M, Escamez MJ, Gonzalez-Martin A, et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004; 64:5632-42.
13. Streck CJ, Zhang Y, Zhou J, Ng C, Nathwani AC, Davidoff AM. Adeno-associated virus vector-mediated delivery of pigment epithelium-derived factor restricts neuroblastoma angiogenesis and growth. J Pediatr Surg 2005; 40:236-43.
14. Yang H, Cheng R, Liu G, Zhong Q, Li C, Cai W, et al. PEDF inhibits growth of retinoblastoma by antiangiogenic activity. Cancer Sci 2009.
15. Gao G, Li Y, Gee S, Dudley A, Fant J, Crosson C, et al. Downregulation of vascular endothelial growth factor and upregulation of pigment epithelium-derived factor: a possible mechanism for the anti-angiogenic activity of plasminogen kringle 5. J Biol Chem 2002; 277:9492-7.
16. Gao G, Li Y, Zhang D, Gee S, Crosson C, Ma J. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001; 489:270-6.
17. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium- derived factor. Proc Natl Acad Sci USA 2001; 98:2593-7.
18. Halin S, Wikstrom P, Rudolfsson SH, Stattin P, Doll JA, Crawford SE, et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 2004; 64:5664-71.
19. Uehara H, Miyamoto M, Kato K, Ebihara Y, Kaneko H, Hashimoto H, et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004; 64:3533-7.
20. Takenaka K, Yamagishi S, Jinnouchi Y, Nakamura K, Matsui T, Imaizumi T. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci 2005; 77:3231-41.
21. Cai J, Parr C, Watkins G, Jiang WG, Boulton M. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 2006; 12:3510-7.
22. Crawford SE, Stellmach V, Ranalli M, Huang X, Huang L, Volpert O, et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001; 114:4421-8. (Pubitemid 34082862)
23. Guan M, Yam HF, Su B, Chan KP, Pang CP, Liu WW, et al. Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 2003; 56:277-82.
24. Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003; 9:774-80.
25. Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K, Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 2004; 40:252-9.
26. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-9. (Pubitemid 20066716)
27. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995; 87:1237-45.
28. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, et al. Upregulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol 2008; 110:445-51.
29. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003; 162:1789-806. (Pubitemid 36613038)
30. Mizokami K, Kakeji Y, Oda S, Irie K, Yonemura T, Konishi F, et al. Clinicopathologic significance of hypoxia-inducible factor 1alpha overexpression in gastric carcinomas. J Surg Oncol 2006; 94:149-54.
31. Yeo E-J, Chun Y-S, Cho Y-S, Kim J, Lee J-C, Kim M-S, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95:516-25. (Pubitemid 36511622)
32. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A, et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis and vessel maturation. J Natl Cancer Inst 2004; 96:946-56.
33. Zhu B, Lu L, Cai W, Yang X, Li C, Yang Z, et al. Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther 2007; 6:3297-306.
34. Lu L, Yang Z, Zhu B, Fang S, Yang X, Cai W, et al. Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett 2007; 257:97-106.
35. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8.